Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting Adenosine Receptor Signaling in Cancer Immunotherapy
Kevin Sek, Christina Mølck, Gregory D. Stewart, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 12, pp. 3837-3837
Open Access | Times Cited: 170

Showing 1-25 of 170 citing articles:

Turning cold tumors into hot tumors by improving T-cell infiltration
Yuan‐Tong Liu, Zhi‐Jun Sun
Theranostics (2021) Vol. 11, Iss. 11, pp. 5365-5386
Open Access | Times Cited: 522
NK Cell Metabolism and Tumor Microenvironment
Iñigo Terrén, Ane Orrantia, Joana Vitallé, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 361
Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker
Zhengyi Wang, Xiaoying Wu
Cancer Medicine (2020) Vol. 9, Iss. 21, pp. 8086-8121
Open Access | Times Cited: 142
CD39/CD73/A2AR pathway and cancer immunotherapy
Chenglai Xia, Shuanghong Yin, Kenneth K.W. To, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 142
CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy
Lauren Giuffrida, Kevin Sek, Melissa A. Henderson, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 141
Current Strategies to Enhance Delivery of Drugs across the Blood–Brain Barrier
Raluca Ioana Teleanu, Manuela Daniela Preda, Adelina-Gabriela Niculescu, et al.
Pharmaceutics (2022) Vol. 14, Iss. 5, pp. 987-987
Open Access | Times Cited: 112
International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update
Adriaan P. IJzerman, Kenneth A. Jacobson, Christa E. Müller, et al.
Pharmacological Reviews (2022) Vol. 74, Iss. 2, pp. 340-372
Open Access | Times Cited: 106
Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions
Chenyue Zhang, Chenxing Zhang, Haiyong Wang
Cancer Letters (2023) Vol. 562, pp. 216182-216182
Closed Access | Times Cited: 55
Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy
Yuqing Cao, Xiaoyu Wang, Tianqiang Jin, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 120
Unleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy?
Aviad Ben‐Shmuel, Guy Biber, Mira Barda‐Saad
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 117
Tuning the Tumor Myeloid Microenvironment to Fight Cancer
Nadine S. Jahchan, Adriana M. Mujal, Joshua L. Pollack, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 111
Regulatory T cell targeting in cancer: Emerging strategies in immunotherapy
Sundee Dees, Rajkumar Ganesan, Sanjaya Singh, et al.
European Journal of Immunology (2020) Vol. 51, Iss. 2, pp. 280-291
Open Access | Times Cited: 99
LAG3: The Biological Processes That Motivate Targeting This Immune Checkpoint Molecule in Human Cancer
Cinzia Solinas, Edoardo Migliori, Pushpamali De Silva, et al.
Cancers (2019) Vol. 11, Iss. 8, pp. 1213-1213
Open Access | Times Cited: 89
Immune checkpoint molecules. Possible future therapeutic implications in autoimmune diseases
Chuan Huang, Hao‐Xian Zhu, Yuan Yao, et al.
Journal of Autoimmunity (2019) Vol. 104, pp. 102333-102333
Closed Access | Times Cited: 80
Genetic and pharmacological targeting of A2a receptor improves function of anti-mesothelin CAR T cells
Elham Masoumi, Leila Jafarzadeh, Hamid Reza Mirzaei, et al.
Journal of Experimental & Clinical Cancer Research (2020) Vol. 39, Iss. 1
Open Access | Times Cited: 71
Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End
Angeliki Datsi, Rüdiger V. Sorg
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 70
Applying nanotechnology to boost cancer immunotherapy by promoting immunogenic cell death
Lvqin Fu, Xianbin Ma, Yuan‐Tong Liu, et al.
Chinese Chemical Letters (2021) Vol. 33, Iss. 4, pp. 1718-1728
Closed Access | Times Cited: 59
The CD38 glycohydrolase and the NAD sink: implications for pathological conditions
Julianna D. Zeidler, Kelly A. Hogan, Guillermo Agorrody, et al.
AJP Cell Physiology (2022) Vol. 322, Iss. 3, pp. C521-C545
Open Access | Times Cited: 47
Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors
Emerson A. Lim, Johanna C. Bendell, Gerald S. Falchook, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 22, pp. 4871-4884
Open Access | Times Cited: 44
Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death
Xuhui Bao, Liyi Xie
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 42
Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastoma
Shannon Coy, Shu Wang, Sylwia A. Stopka, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 42
The Immune Regulatory Role of Adenosine in the Tumor Microenvironment
Jianlei Xing, Jinhua Zhang, Jinyan Wang
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14928-14928
Open Access | Times Cited: 30
NK Cells in Cancer: Mechanisms of Dysfunction and Therapeutic Potential
Federica Portale, Diletta Di Mitri
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9521-9521
Open Access | Times Cited: 26
Review immune response of targeting CD39 in cancer
Yao Liu, Zhongliang Li, Xiaoguang Zhao, et al.
Biomarker Research (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 24
CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
Erika Y. Faraoni, Kanchan Singh, Vidhi Chandra, et al.
Cancer Research (2023) Vol. 83, Iss. 7, pp. 1111-1127
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top